Merus B.V. Aktie

43,80 EUR +1,20 EUR +2,82 %

09:59:02

FSE

50,76 USD -4,38 USD -7,94 %

27.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.3,11 Mrd. EUR

Div. Rendite0,00%

WKNA2AKFX

ISINNL0011606264

SymbolMRUS

Merus B.V. Aktien News

Sortieren:Datum Meistgelesen

27.05.25GlobeNewswireMerus to Present at Upcoming Investor Conferences

22.05.25GlobeNewswireMerus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

15.05.25GlobeNewswireMerus Announces the Journal Publication of Petosemtamab Mechanism of Action

WerbungMerus B.V.-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

08.05.25GlobeNewswireMerus to Present at BofA Securities 2025 Health Care Conference

07.05.25GlobeNewswireMerus Announces Financial Results for the First Quarter 2025 and Provides Business Update

23.04.25GlobeNewswireMerus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

01.04.25GlobeNewswireMerus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

27.02.25GlobeNewswireMerus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

25.02.25GlobeNewswireMerus to Present at Upcoming Investor Conferences

18.02.25GlobeNewswirePetosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

13.02.25GlobeNewswireMerus to Present at Citi's 2025 Virtual Oncology Leadership Summit

05.02.25GlobeNewswireNew England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

13.01.25GlobeNewswireMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

16.12.24GlobeNewswireMerus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

07.12.24GlobeNewswireMerus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

04.12.24GlobeNewswireMerus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

02.12.24GlobeNewswireMerus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

01.12.24GlobeNewswireMerus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

06.11.24GlobeNewswireMerus to Present at Upcoming Investor Conferences

05.11.24GlobeNewswireMerus Receives FDA extension of PDUFA for zenocutuzumab

31.10.24GlobeNewswireMerus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

30.09.24GlobeNewswireMerus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

17.09.24GlobeNewswireMerus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

06.08.24GlobeNewswireMerus to Present at Canaccord Genuity’s 44th Annual Growth Conference

01.08.24GlobeNewswireMerus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

24.07.24GlobeNewswireMerus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

08.07.24GlobeNewswireMerus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

01.07.24GlobeNewswireMerus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

03.06.24GlobeNewswireMerus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

02.06.24GlobeNewswireMerus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

30.05.24GlobeNewswireMerus Announces Pricing of Upsized Public Offering of Common Shares

29.05.24GlobeNewswireMerus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

28.05.24GlobeNewswireMerus N.V. Announces Proposed Public Offering of Common Shares

28.05.24GlobeNewswireMerus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

23.05.24GlobeNewswireMerus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

23.05.24GlobeNewswireMerus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

13.05.24GlobeNewswirePetosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

08.05.24GlobeNewswireMerus Announces Financial Results for the First Quarter 2024 and Provides Business Update

06.05.24GlobeNewswireMerus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

24.04.24GlobeNewswireMerus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Merus B.V. News

Merus B.V. News: auf dieser Seite finden Sie alle Merus B.V. News und Nachrichten zur Merus B.V. Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merus B.V. News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merus B.V. News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.